MedTrace Logo

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

NCT03351842 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2017-12-19

No results posted yet for this study

Summary

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

Conditions

  • Chemotherapy, Adjuvant
  • Lung Adenocarcinoma, Stage I
  • Treatment
  • Histological Type of Neoplasm

Interventions

DRUG

cis Platinum/Carboplatin, Pemetrexed Disodium

Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours

PROCEDURE

Undergo surgery

Therapeutic conventional surgery, R0 resection

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2019-09-01
Completion
2024-09-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03351842 on ClinicalTrials.gov